1. Home
  2. JRS vs IVVD Comparison

JRS vs IVVD Comparison

Compare JRS & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Real Estate Income Fund of Beneficial Interest

JRS

Nuveen Real Estate Income Fund of Beneficial Interest

SELL

Current Price

$7.48

Market Cap

210.6M

Sector

Finance

ML Signal

SELL

Logo Invivyd Inc.

IVVD

Invivyd Inc.

SELL

Current Price

$0.50

Market Cap

212.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
JRS
IVVD
Founded
2001
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
210.6M
212.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
JRS
IVVD
Price
$7.48
$0.50
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $10.00
AVG Volume (30 Days)
60.6K
★ 3.4M
Earning Date
01-01-0001
11-16-2026
Dividend Yield
★ 8.87%
N/A
EPS Growth
N/A
★ 79.02
EPS
★ N/A
N/A
Revenue
N/A
★ $53,426,000.00
Revenue This Year
N/A
$12.92
Revenue Next Year
N/A
$44.18
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 110.47
52 Week Low
$7.12
$0.52
52 Week High
$8.90
$3.01

Technical Indicators

Market Signals
Indicator
JRS
IVVD
Relative Strength Index (RSI) 44.01 35.94
Support Level $7.12 N/A
Resistance Level $8.32 $0.66
Average True Range (ATR) 0.15 0.05
MACD -0.00 0.00
Stochastic Oscillator 22.52 13.27

Price Performance

Historical Comparison
JRS
IVVD

About JRS Nuveen Real Estate Income Fund of Beneficial Interest

Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund s investment objective is to provide total return through high current income and capital appreciation.

About IVVD Invivyd Inc.

Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.

Share on Social Networks: